Mechanism of action of the fat mass and obesity-associated gene in the development and progression of metabolic dysfunction-associated fatty liver disease and related targeted therapies
- VernacularTitle:脂肪量和肥胖相关基因在代谢相关脂肪性肝病发生发展中的作用机制及相关靶向治疗
- Author:
Zhaoquan PAN
1
;
Xudong LIU
2
;
Weiqiang TAN
1
;
Xiaoke RAN
1
;
Yuan YUAN
1
;
Xinfeng LOU
1
Author Information
- Publication Type:Review
- Keywords: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Non-alcoholic Fatty Liver Disease; Lipid Metabolism Disorders; Genetic Therapy
- From: Journal of Clinical Hepatology 2025;41(6):1167-1173
- CountryChina
- Language:Chinese
- Abstract: Metabolic dysfunction-associated fatty liver disease （MAFLD） is a common chronic liver disease with the pathological feature of lipid accumulation in the liver， and it is closely associated with liver metabolic disorders. The latest research has shown that the pathogenesis of MAFLD is associated with the abnormal expression of specific genes， especially the fat mass and obesity-associated （FTO） gene. The abnormal activity of the FTO gene may lead to an imbalance in liver lipid metabolism， which manifests as the increase in fatty acid synthesis and the reduction in fatty acid oxidation， thereby promoting liver fat deposition and inflammatory response. Therefore， regulating the expression or activity of the FTO gene is considered one of the potential strategies for the treatment of MAFLD. At present， drug research targeting the function of the FTO gene has achieved preliminary results， and inhibition of the activity of the FTO gene can help to regulate liver lipid metabolism and alleviate liver inflammatory injury. This article reviews the mechanism of action of the FTO gene in the development and progression of MAFLD， summarizes the advances in drug research on the FTO gene and related metabolic pathways in recent years， and analyzes their application prospect in research and treatment.
